Previously, we developed a non-replicating recombinant baculovirus coated with human endogenous retrovirus envelope protein (AcHERV) for enhanced cellular delivery of human papillomavirus (HPV) 16L1 DNA. Here, we report the immunogenicity of an AcHERV-based multivalent HPV nanovaccine in which the L1 segments of HPV 16, 18, and 58 genes were inserted into a single baculovirus genome of AcHERV. To test whether gene expression levels were affected by the order of HPV L1 gene insertion, we compared the efficacy of bivalent AcHERV vaccines with the HPV 16L1 gene inserted ahead of the 18L1 gene (AcHERV-HP16/18L1) with that of AcHERV with the HPV 18L1 gene inserted ahead of the 16L1 gene (AcHERV-HP18/16L1). Regardless of the order, the bivalent AcHERV DNA vaccines retained the immunogenicity of monovalent AcHERV-HP16L1 and AcHERV-HP18L1 DNA vaccines. Moreover, the immunogenicity of bivalent AcHERV-HP16/18L1 was not significantly different from that of AcHERV-HP18/16L1. In challenge tests, both bivalent vaccines provided complete protection against HPV 16 and 18 pseudotype viruses. Extending these results, we found that a trivalent AcHERV nanovaccine encoding HPV 16L1, 18L1, and 58L1 genes (AcHERV-HP16/18/58L1) provided high levels of humoral and cellular immunogenicity against all three subtypes. Moreover, mice immunized with the trivalent AcHERV-based nanovaccine were protected from challenge with HPV 16, 18, and 58 pseudotype viruses. These results suggest that trivalent AcHERV-HPV16/18/58L1 could serve as a potential prophylactic baculoviral nanovaccine against concurrent infection with HPV 16, 18, and 58.
References
[1]
zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nature reviews Cancer 2: 342–350. doi: 10.1038/nrc798
[2]
Dell G, Gaston K (2001) Human papillomaviruses and their role in cervical cancer. Cellular and molecular life sciences: CMLS 58: 1923–1942. doi: 10.1007/pl00000827
[3]
Daftarian P, Mansour M, Benoit AC, Pohajdak B, Hoskin DW, et al. (2006) Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion. Vaccine 24: 5235–5244. doi: 10.1016/j.vaccine.2006.03.079
[4]
Ault KA, Giuliano AR, Edwards RP, Tamms G, Kim LL, et al. (2004) A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine. Vaccine 22: 3004–3007. doi: 10.1016/j.vaccine.2004.02.020
[5]
Chan PK, Li WH, Chan MY, Ma WL, Cheung JL, et al. (1999) High prevalence of human papillomavirus type 58 in Chinese women with cervical cancer and precancerous lesions. Journal of medical virology 59: 232–238. doi: 10.1002/(sici)1096-9071(199910)59:2<232::aid-jmv18>3.0.co;2-7
[6]
Chan PK (2012) Human papillomavirus type 58: the unique role in cervical cancers in East Asia. Cell & bioscience 2: 17. doi: 10.1186/2045-3701-2-17
[7]
Kuck D, Lau T, Leuchs B, Kern A, Muller M, et al. (2006) Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. Journal of virology 80: 2621–2630. doi: 10.1128/jvi.80.6.2621-2630.2006
[8]
Ferraro B, Morrow MP, Hutnick NA, Shin TH, Lucke CE, et al. (2011) Clinical applications of DNA vaccines: current progress. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 53: 296–302. doi: 10.1093/cid/cir334
[9]
Liu MA (2010) Immunologic basis of vaccine vectors. Immunity 33: 504–515. doi: 10.1016/j.immuni.2010.10.004
[10]
Bodles-Brakhop AM, Draghia-Akli R (2008) DNA vaccination and gene therapy: optimization and delivery for cancer therapy. Expert review of vaccines 7: 1085–1101. doi: 10.1586/14760584.7.7.1085
[11]
Bolhassani A, Safaiyan S, Rafati S (2011) Improvement of different vaccine delivery systems for cancer therapy. Molecular cancer 10: 3. doi: 10.1186/1476-4598-10-3
[12]
Chen CY, Liu HJ, Tsai CP, Chung CY, Shih YS, et al. (2010) Baculovirus as an avian influenza vaccine vector: differential immune responses elicited by different vector forms. Vaccine 28: 7644–7651. doi: 10.1016/j.vaccine.2010.09.048
[13]
Cho HJ, Han SE, Im S, Lee Y, Kim YB, et al. (2011) Maltosylated polyethylenimine-based triple nanocomplexes of human papillomavirus 16L1 protein and DNA as a vaccine co-delivery system. Biomaterials 32: 4621–4629. doi: 10.1016/j.biomaterials.2011.03.004
[14]
Best SR, Peng S, Juang CM, Hung CF, Hannaman D, et al. (2009) Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. Vaccine 27: 5450–5459. doi: 10.1016/j.vaccine.2009.07.005
[15]
Ohlschlager P, Spies E, Alvarez G, Quetting M, Groettrup M (2011) The combination of TLR-9 adjuvantation and electroporation-mediated delivery enhances in vivo antitumor responses after vaccination with HPV-16 E7 encoding DNA. International journal of cancer Journal international du cancer 128: 473–481. doi: 10.1002/ijc.25344
[16]
Brandsma JL, Shlyankevich M, Zhang L, Slade MD, Goodwin EC, et al. (2004) Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection. Journal of virology 78: 116–123. doi: 10.1128/jvi.78.1.116-123.2004
[17]
Kaufmann AM, Stern PL, Rankin EM, Sommer H, Nuessler V, et al. (2002) Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clinical cancer research: an official journal of the American Association for Cancer Research 8: 3676–3685.
[18]
Cho HJ, Oh YK, Kim YB (2011) Advances in human papilloma virus vaccines: a patent review. Expert opinion on therapeutic patents 21: 295–309. doi: 10.1517/13543776.2011.551114
[19]
Lee HJ, Park N, Cho HJ, Yoon JK, Van ND, et al. (2010) Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1. Vaccine 28: 1613–1619. doi: 10.1016/j.vaccine.2009.11.044
[20]
Kost TA, Condreay JP (2002) Recombinant baculoviruses as mammalian cell gene-delivery vectors. Trends in biotechnology 20: 173–180. doi: 10.1016/s0167-7799(01)01911-4
[21]
Lung O, Westenberg M, Vlak JM, Zuidema D, Blissard GW (2002) Pseudotyping Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV): F proteins from group II NPVs are functionally analogous to AcMNPV GP64. Journal of virology 76: 5729–5736. doi: 10.1128/jvi.76.11.5729-5736.2002
[22]
Wilson S, Baird M, Ward VK (2008) Delivery of vaccine peptides by rapid conjugation to baculovirus particles. Vaccine 26: 2451–2456. doi: 10.1016/j.vaccine.2008.03.027
[23]
Buck CB, Pastrana DV, Lowy DR, Schiller JT (2004) Efficient intracellular assembly of papillomaviral vectors. Journal of virology 78: 751–757. doi: 10.1128/jvi.78.2.751-757.2004
[24]
Lee HJ, Hur YK, Cho YD, Kim MG, Lee HT, et al. (2012) Immunogenicity of bivalent human papillomavirus DNA vaccine using human endogenous retrovirus envelope-coated baculoviral vectors in mice and pigs. PloS one 7: e50296. doi: 10.1371/journal.pone.0050296
[25]
Choi JY, Gwon YD, Kim JK, Cho YD, Heo YK, et al. (2013) Protective Efficacy of a Human Endogenous Retrovirus Envelope-Coated, Nonreplicable, Baculovirus-Based Hemagglutin Vaccine against Pandemic Influenza H1N1 2009. PloS one 8: e80762. doi: 10.1371/journal.pone.0080762
[26]
Nieto K, Stahl-Hennig C, Leuchs B, Muller M, Gissmann L, et al. (2012) Intranasal vaccination with AAV5 and 9 vectors against human papillomavirus type 16 in rhesus macaques. Human gene therapy 23: 733–741. doi: 10.1089/hum.2011.202
[27]
Wheeler CM, Castellsague X, Garland SM, Szarewski A, Paavonen J, et al. (2012) Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. The lancet oncology 13: 100–110. doi: 10.1016/s1470-2045(11)70287-x
[28]
Hara H, Honda A, Suzuki H, Sata T, Matsukura T (2004) Detection of human papillomavirus type 58 in polydactylous Bowen's disease on the fingers and toes of a woman - concurrent occurrence of invasive vulval and cervical carcinomas. Dermatology 209: 218–222. doi: 10.1159/000079893
[29]
Bao YP, Li N, Smith JS, Qiao YL (2008) Human papillomavirus type distribution in women from Asia: a meta-analysis. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society 18: 71–79. doi: 10.1111/j.1525-1438.2007.00959.x
[30]
Zhang T, Xu Y, Qiao L, Wang Y, Wu X, et al. (2010) Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types. Vaccine 28: 3479–3487. doi: 10.1016/j.vaccine.2010.02.057
[31]
Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL (2006) Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24 Suppl 3S3/26–34. doi: 10.1016/j.vaccine.2006.05.026
[32]
Kwag HL, Kim HJ, Chang DY (2012) The production and immunogenicity of human papillomavirus type 58 virus-like particles produced in Saccharomyces cerevisiae. J Microbiol 50: 813–820. doi: 10.1007/s12275-012-2292-1
[33]
Bonanni P, Boccalini S, Bechini A (2009) Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine 27 Suppl 1A46–53. doi: 10.1016/j.vaccine.2008.10.085
[34]
Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, et al. (2011) HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 29: 2011–2014. doi: 10.1016/j.vaccine.2011.01.001
[35]
Herrero R (2009) Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. The Journal of infectious diseases 199: 919–922. doi: 10.1086/597308
[36]
Scherpenisse M, Schepp RM, Mollers M, Meijer CJ, Berbers GA, et al. (2013) Characteristics of HPV-Specific Antibody Responses Induced by Infection and Vaccination: Cross-Reactivity, Neutralizing Activity, Avidity and IgG Subclasses. PloS one 8: e74797. doi: 10.1371/journal.pone.0074797
[37]
Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, et al. (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nature medicine 13: 857–861. doi: 10.1038/nm1598
